Motilium Fastmelts (Domperidone)

Domperidone, the active ingredient in Motilium Fastmelts, is a dopamine antagonist presented as an orally disintegrating tablet for oral use. It treats nausea, vomiting, gastroparesis and functional dyspepsia in adults. The formulation rapidly dissolves on the tongue, allowing absorption without water.

GNH USA supplies Motilium Fastmelts as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global markets and offers reliable logistics support through established distribution networks.

Domperidone acts on gastrointestinal motility and the emetic pathway, providing therapeutic benefit in several digestive disorders.

- Nausea and vomiting: Reduces the frequency and severity of symptoms in patients with acute, postoperative or chemotherapy‑induced nausea. - Gastroparesis: Improves gastric emptying and alleviates related discomfort in patients with delayed gastric motility. - Functional dyspepsia: Relieves upper‑abdominal fullness and early satiety by enhancing gastric transit.

Domperidone is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dry mouth - Headache - Abdominal cramps - Dizziness

Serious or Rare Side Effects: - Cardiac arrhythmia or QT‑interval prolongation - Extrapyramidal symptoms such as dystonia - Severe allergic reaction (anaphylaxis)

Before prescribing domperidone, clinicians should consider several safety measures.

- Assess cardiac risk: evaluate QT interval and electrolyte status prior to initiation. - Avoid use in patients with known prolactin‑secreting tumors or endocrine disorders. - Monitor for signs of endocrine disturbance, such as galactorrhea or menstrual changes. - Use with caution in hepatic impairment; dose adjustment may be required. - Do not co‑administer with strong CYP3A4 inhibitors without monitoring. - Store at ambient temperature: keep in the original pack, protect from moisture.

Domperidone may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase plasma levels and risk of cardiac toxicity. - QT‑prolonging agents (e.g., quinidine, sotalol): additive risk of arrhythmia. - Antifungal agents (e.g., itraconazole): raise exposure and potential toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effectiveness. - Antacids containing aluminum or magnesium: can decrease domperidone absorption. - Macrolide antibiotics (e.g., clarithromycin): may require dose adjustment and ECG monitoring.